The purpose of this study is to evaluate how safe and effective Raludotatug Deruxtecan is in treating these types of gastrointestinal cancers. The study will look at whether the treatment helps to shrink the tumors and how long any improvement lasts. The study will also collect information about any side effects or unwanted reactions that people may experience while receiving the treatment. People taking part in this study will have already received previous treatment for their cancer before joining.

During the study, participants will receive the study medication for up to 12 months. Doctors will monitor how the cancer responds to the treatment and will check for any side effects. The study will measure things like whether the tumors get smaller, how long the treatment works, how long people live without their cancer getting worse, and overall survival. This is an open-label study, which means that both the doctors and the participants will know what treatment is being given.

The purpose of this study is to find the best amount and timing of indocyanine green to create enough difference in brightness between the tumor and normal tissue, and to check whether this glowing effect can help surgeons accurately identify the edges of tumors during surgery. The study will look at how well the fluorescence imaging, which is a technique that uses special cameras to see the glowing substance, matches with what is found when tissue is examined under a microscope after removal. Researchers will also count how many additional glowing areas are found and confirmed to be cancer, as well as cases where the glow incorrectly suggests cancer when there is none or misses cancer that is present.

During the study, patients who are already planned to have surgery to remove their cancer will receive an infusion of indocyanine green before or during their operation. Surgeons will use special cameras that can detect the fluorescence to look at the tumor area and the surrounding tissue. The removed tissue and any lymph nodes will be examined both with the fluorescence camera and later under a microscope to compare the results. The study will measure the brightness difference between tumor and normal tissue, check whether the edges of the removed tissue are free of cancer cells, and record any side effects that occur. The goal is to determine if this imaging method can help surgeons remove cancer more completely while preserving healthy tissue.

The medication GSK5764227 is administered through intravenous infusion, which means it is given directly into a vein. The drug comes in the form of a powder that is converted into a solution before being administered. The main purpose of this research is to determine how well this new treatment works and how safe it is for patients who have already received previous treatments for their gastrointestinal cancer.

This is a combined Phase 1b/2 study, which means it will assess both the safety and effectiveness of the treatment. The study is “open-label,” which means all participants will know which treatment they are receiving. Some participants will receive different doses of the medication to help determine which amount works best while maintaining safety. The study will include multiple medical centers to ensure a thorough evaluation of the treatment.

The purpose of the study is to assess the short-term effects of these cancer treatments on speech perception in noise. Participants will undergo various assessments to measure changes in their ability to understand speech in noisy settings, as well as changes in their hearing and cognitive functions. The study will also evaluate the impact of these treatments on the participants’ quality of life related to hearing. The trial will follow participants from the start of their treatment and include follow-up visits to monitor any changes over time.

By participating in this study, researchers aim to gain a better understanding of how cancer treatments affect important aspects of daily life, such as communication and cognitive abilities. This information could help improve future treatment plans and support services for individuals undergoing cancer therapy. The study is expected to continue until the end of 2031, with recruitment starting in August 2024.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The purpose of the study is to assess how well these drug combinations work and how safe they are for patients with these types of cancers. Participants will receive the treatments over a period of up to 24 months. The study will monitor the participants’ health and any side effects they may experience. The goal is to understand the potential benefits and risks of these treatments for people with advanced upper gastrointestinal tract cancers.

Throughout the study, participants will undergo regular check-ups and assessments to track their response to the treatment. This includes measuring the size of the cancer and checking for any changes in the participants’ health. The study aims to provide valuable information that could help improve treatment options for people with these challenging types of cancer.

The purpose of this study is to evaluate how safe it is to use Lanreotide in combination with Metformin in patients with these specific types of tumors. Participants in the study will receive both medications and will be monitored for any side effects or changes in their condition. The study is designed to observe how the body responds to this combination of treatments over a period of time. Participants will receive regular check-ups, including physical exams and laboratory tests, to ensure their safety and to gather information about the treatment’s effects.

This study is open-label, meaning that both the participants and the researchers know which treatments are being administered. It is a pilot study, which means it is an initial, smaller-scale study to gather preliminary data. The study will help researchers understand the potential benefits and risks of using Lanreotide and Metformin together in treating advanced gastrointestinal or lung carcinoids. The information gathered from this study may contribute to future research and treatment options for these types of tumors.

The purpose of the study is to understand if a pre-surgery dose of corticosteroids can reduce the risk of major complications after surgery. Participants will be randomly assigned to receive either the corticosteroid treatment or a placebo before their surgery. The study will monitor the occurrence of any significant complications within 30 days after the surgery. Additionally, the study will look at other factors such as overall survival, disease-free survival, and the frequency of infections after surgery.

Throughout the study, the safety of the treatment will be closely observed, with particular attention to side effects like high blood sugar and issues with electrolytes, which are minerals in the blood that help with various body functions. The study will also assess how well surgical wounds heal by checking them 30 days after the surgery. The trial is expected to continue until November 2026, with the goal of providing valuable insights into the benefits of corticosteroids in surgical oncology for digestive cancer.

Participants in the study will receive treatment with both Capecitabine, which is taken orally as a tablet, and Oxaliplatin, which is given through an intravenous infusion. The study will monitor how the body absorbs and breaks down these medications over a period of time. Researchers are particularly interested in understanding the differences in medication processing between individuals with the genetic variation and those without it. This information could help tailor treatments to improve outcomes and reduce side effects for patients with gastrointestinal carcinoma.

The study will also look at the occurrence of a side effect known as hand-foot syndrome, which can cause redness, swelling, and pain in the hands and feet. By examining the relationship between the genetic variation and the development of this side effect, the study aims to provide insights that could lead to better management of treatment-related symptoms. The trial is expected to continue until the end of 2026, with the goal of enhancing the understanding of how genetic factors influence the treatment of gastrointestinal carcinoma.